Business context and reporting period
The supplied filing is Emerald Medical Applications Corp.’s Form 10-K for the fiscal year ended December 31, 2015—not a filing identifying Quantum X Labs Inc. The company, formerly Zaxis International Inc., completed a reverse merger in July 2015 and operates through its Israeli subsidiary. Its business is developing and marketing DermaCompare, cloud and mobile imaging software intended to help medical professionals track skin lesions and support early melanoma detection.
The company had begun marketing the product but had not generated revenue in either 2015 or 2014. It reported distribution arrangements covering Italy, the Netherlands, Australia, New Zealand and Oceania, and described further market expansion as planned or under negotiation.
Financial performance and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $740,197 | $0 |
| General and administrative expense | $7,296,798 | $116,863 |
| Net loss | $8,756,267 | $105,049 |
| Net loss per share | $0.81 | $0.01 |
| Cash used in operating activities | $1,301,823 | $110,694 |
| Cash and cash equivalents at year-end | $115,449 | $14,411 |
Gross margin is not meaningful because the company reported no revenue. The 2015 loss included $5.34 million of warrant expense and $397,547 of employee-option expense, as well as $885,984 of shares issued for services and a $678,027 loss on settlement of debt. These items are substantially non-cash; operating cash use was $1.30 million.
At December 31, 2015, current assets were $141,246 and current liabilities were $288,775, producing negative working capital of $147,529. Total assets were $162,366 and stockholders’ deficit was $126,409. Current liabilities included $119,974 of short-term notes payable, $29,719 of convertible notes and $19,285 of accrued interest. The $119,974 Chief Scientist Ministry of Israel loan bears 17% interest and is payable when the company generates sales revenue. No cash-flow hedging or off-balance-sheet arrangements were reported.
Changes versus the prior comparable period
- Revenue remained zero, while net loss increased from $105,049 to $8.76 million, primarily reflecting higher operating expenses and significant share- and warrant-based compensation.
- Operating cash use rose from $110,694 to $1.30 million. Year-end cash increased to $115,449, supported by $989,974 of financing proceeds reported for 2015.
- Current liabilities increased from $137,635 to $288,775, and negative working capital widened from $97,507 to $147,529.
- R&D spending began in 2015, totaling $740,197. The company completed a commercial model of DermaCompare and commenced marketing.
Outlook, risks and unusual items
Management expected to begin generating revenue in the first half of fiscal 2016 and said it might need up to an additional $1.5 million over the next 12 months to implement its plan and fund operations. This is an expectation, not reported revenue or firm guidance. The independent auditor issued an unqualified opinion on the financial statements with an explanatory going-concern paragraph, citing recurring losses, no revenue and negative operating cash flow; substantial doubt about the company’s ability to continue as a going concern remains.
Key risks include the need for additional capital, uncertain physician and patient adoption, competition, product reliability and data security, limited intellectual-property protection (no patent filings or registered trademarks reported), and possible reimbursement or regulatory changes. The company stated that its product was not subject to FDA or other governmental approval, while also noting that regulatory changes could affect operations. It had no direct sales force and depended on distributors, partners and planned marketing efforts.
Management found disclosure controls ineffective and reported material weaknesses in internal control over financial reporting, including insufficient accounting personnel to document complex transactions and support adequate reporting. Corrective actions were planned to begin in the second quarter of 2016. The auditor did not attest to internal controls.
Capital structure and governance warrant attention: 15.33 million shares were outstanding at year-end 2015, and the filing reported 18.62 million outstanding at March 31, 2016. Substantial warrants and options could cause dilution. The CEO held 29.4% of shares as of March 31, 2016, and officers and directors were reported to hold 40.25% as a group. The filing also reports post-year-end warrant conversions and share issuances.
Most important facts for investors to verify
- Confirm issuer identity: this filing names Emerald Medical Applications Corp. (ticker MRLA), not Quantum X Labs Inc.
- Check subsequent filings for actual DermaCompare revenue, customer adoption, and whether the first-half 2016 revenue expectation was achieved.
- Verify cash availability, debt terms and repayment conditions, and whether the stated additional capital was raised; assess the going-concern risk.
- Reconcile the filing’s financing and cash-flow disclosures, including its reported $989,974 of 2015 financing, and confirm year-end cash. The cash-flow statement contains an apparent inconsistency in the comparative ending-cash figure; the balance sheet reports $115,449 for 2015 and $14,411 for 2014.
- Review the valuation and dilution effects of warrants, options, shares issued for services, and the CEO’s milestone-based Class E warrants.
- Follow remediation of the reported control weaknesses and verify whether subsequent auditor or management disclosures identify further issues.